Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Iowa City, Iowa 52242


Purpose:

The purpose of this study is to determine if the events leading to smoking-associated centrilobular and paraseptal emphysema are caused by a failure of the lungs' inherent mechanisms to block hypoxic pulmonary vasoconstriction (HPV) in areas of smoking-induced inflammation.


Study summary:

Overall goals of this study are to 1) determine the effects on sildenafil on the heterogeneity perfused blood volume in smokers susceptible to emphysema using dual energy CT 2) utilize pulmonary blood volume heterogeneity as an image-based biomarker to differentiate normal and susceptible smokers.


Criteria:

Inclusion Criteria: - Must be between the ages of 30 and 60. - Must be currently smoking at least 1/2 pack/day (confirmed with cotinine level). - Must have pulmonary function test (PFT) results that meet the following: - Forced Expiratory Volume at one second (FEV1)/Forced Vital Capacity (FVC) > 70% - Forced Expiratory Flow at 25-75% (FEF25-75) > 79% of predicted - FVC greater than 80% of predicted - Must be able to give informed consent for self. Exclusion Criteria: - Pregnant or breastfeeding females. - Body Mass Index (BMI) greater than 32. - Weight of greater than 220 pounds (100 kg). - Allergies to shell fish, seafood, eggs or iodine. - Heart disease, kidney disease or diabetes. - Diagnosis of asthma. - Usage of any medications that are known to affect the heart or lungs (contraceptives, anti-depressants, analgesics EXCEPT aspirin, antihypertensives, and medications for osteoporosis and gastrointestinal diseases will be allowed). - Any metal in or on the body between the nose and the abdomen. - Any major organ system disease (by judgment of study medical team). For the subjects that will receive Sildenafil as part of the study, additional exclusion criteria are as follows: - Nitroglycerin usage. - Prior history of hypersensitivity to Sildenafil.


NCT ID:

NCT03733470


Primary Contact:

Principal Investigator
Eric A Hoffman
University of Iowa


Backup Contact:

N/A


Location Contact:

Iowa City, Iowa 52242
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.